GI treatment options are always evolving. Provide your patients with the treatment regimens they need to relieve symptoms that interfere with their everyday lives. New and effective treatment options will be covered in a variety of DDW sessions this year, including personalized medicine, FMT, IBD and HCV. Below are several sessions on this topic at DDW® 2015 in Washington, DC.

AASLD

Hepatitis C Recommendations for 2015
Sunday, May 17, 10-11:30 a.m.

Hepatology Update: The Year in Review
Saturday, May 16, 2-5 p.m.
Moderators: Paul Martin, MD, and Michael H. Nathanson, MD, PhD

Non-Cirrhotic Portal Hypertension and Congenital Portosystemic Shunts: Multidisciplinary Approach to Recognition, Evaluation and Management
Co-sponsored with NASPGHAN
Sunday, May 17, 4-5:30 p.m.

Prospects for Therapy of Hepatic Fibrosis
Sunday, May 17, 10-11:30 a.m.

AGA

AGA Spring Postgraduate Course: Evidence That Will Change Your Practice: New Advances for Common Clinical Problems
Saturday, May 16, 8:15 a.m.–5:30 p.m.
Sunday, May 17, 8:30 a.m.–12:35 p.m.

AGA Institute Council Global Topic Sessions
Topics include: Biomarkers Validation for Patient Satisfaction: Personalized Medicine at Its Best; Developing Targeted Drug Therapy for GI Disease; Prebiotics, Probiotics, Microbiome and FMT
Saturday, May 16, Monday, May 18, and Tuesday, May 19

Cochrane Symposium: The Next Wave Of Biological Agents For The Treatment of IBD: Evidence From Cochrane Reviews
Sunday, May 17, 8-9:30 a.m.

The Dr. Charles S. Lieber Lecture — New Frontiers: NASH: The Convergence of Inflammation, Fat and Fibrosis and the Path to Treatment
Sunday, May 17, 2-3 p.m.

Digestive Disease Week® (DDW) offers new and exciting programs and data that cross a variety of disciplines in gastroenterology and hepatology. Based on feedback from the societies, several topics have emerged that attendees might find of interest. A blog post relating to each theme will be posted on Mondays on the DDW Blog. Be sure to subscribe to receive an email when the next article is posted. This is post two of five in the series. Read the first post, about current GI controversies, here.